These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 31426928)

  • 1. An Ethical Analysis of Coverage With Evidence Development.
    Carter D; Merlin T; Hunter D
    Value Health; 2019 Aug; 22(8):878-883. PubMed ID: 31426928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coverage with Evidence Development: applications and issues.
    Trueman P; Grainger DL; Downs KE
    Int J Technol Assess Health Care; 2010 Jan; 26(1):79-85. PubMed ID: 20059784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementation of coverage with evidence development schemes for medical devices: A decision tool for late technology adopter countries.
    Kovács S; Kaló Z; Daubner-Bendes R; Kolasa K; Hren R; Tesar T; Reckers-Droog V; Brouwer W; Federici C; Drummond M; Zemplényi AT
    Health Econ; 2022 Sep; 31 Suppl 1(Suppl 1):195-206. PubMed ID: 35322478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coverage with evidence development: an examination of conceptual and policy issues.
    Hutton J; Trueman P; Henshall C
    Int J Technol Assess Health Care; 2007; 23(4):425-32. PubMed ID: 17937829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decision making by NICE: examining the influences of evidence, process and context.
    Cerri KH; Knapp M; Fernández JL
    Health Econ Policy Law; 2014 Apr; 9(2):119-41. PubMed ID: 23688554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coverage with evidence development: the Ontario experience.
    Levin L; Goeree R; Levine M; Krahn M; Easty T; Brown A; Henry D
    Int J Technol Assess Health Care; 2011 Apr; 27(2):159-68. PubMed ID: 21473814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coverage With Evidence Development and Managed Entry in the Funding of Personalized Medicine: Practical and Ethical Challenges for Oncology.
    Lewis JR; Kerridge I; Lipworth W
    J Clin Oncol; 2015 Dec; 33(34):4112-7. PubMed ID: 26460298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.
    Garrison LP; Towse A; Briggs A; de Pouvourville G; Grueger J; Mohr PE; Severens JL; Siviero P; Sleeper M
    Value Health; 2013; 16(5):703-19. PubMed ID: 23947963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme.
    Henry DA; Hill SR; Harris A
    JAMA; 2005 Nov; 294(20):2630-2. PubMed ID: 16304078
    [No Abstract]   [Full Text] [Related]  

  • 10. NICE technology appraisals: working with multiple levels of uncertainty and the potential for bias.
    Brown P; Calnan M
    Med Health Care Philos; 2013 May; 16(2):281-93. PubMed ID: 22198480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A network approach for distinguishing ethical issues in research and development.
    Zwart SD; van de Poel I; van Mil H; Brumsen M
    Sci Eng Ethics; 2006 Oct; 12(4):663-84. PubMed ID: 17199143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New French Coverage with Evidence Development for Innovative Medical Devices: Improvements and Unresolved Issues.
    Martelli N; van den Brink H; Borget I
    Value Health; 2016 Jan; 19(1):17-9. PubMed ID: 26797231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health technology assessment in Australia: a role for clinical registries?
    Scott AM
    Aust Health Rev; 2017 Mar; 41(1):19-25. PubMed ID: 27028134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HEALTH TECHNOLOGY ASSESSMENT, DELIBERATIVE PROCESS, AND ETHICALLY CONTESTED ISSUES.
    Daniels N; van der Wilt GJ
    Int J Technol Assess Health Care; 2016 Jan; 32(1-2):10-5. PubMed ID: 27472157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ethical Challenges Related to Patient Involvement in Health Technology Assessment.
    Vanstone M; Abelson J; Bidonde J; Bond K; Burgess R; Canfield C; Schwartz L; Tripp L
    Int J Technol Assess Health Care; 2019; 35(4):253-256. PubMed ID: 31250778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Framework for systematic identification of ethical aspects of healthcare technologies: the SBU approach.
    Heintz E; Lintamo L; Hultcrantz M; Jacobson S; Levi R; Munthe C; Tranæus S; Östlund P; Sandman L
    Int J Technol Assess Health Care; 2015 Jan; 31(3):124-30. PubMed ID: 26134927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ethics of attaching research conditions to access to new health technologies.
    Holland S; Hope T
    J Med Ethics; 2012 Jun; 38(6):366-71. PubMed ID: 22345547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence-based decision-making within Australia's pharmaceutical benefits scheme.
    Lopert R
    Issue Brief (Commonw Fund); 2009 Jul; 60():1-13. PubMed ID: 19639714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A successful practical application of Coverage with Evidence Development in Australia: Medical Services Advisory Committee interim funding and the PillCam Capsule Endoscopy Register.
    O'Malley SP; Selby WS; Jordan E
    Int J Technol Assess Health Care; 2009 Jul; 25(3):290-6. PubMed ID: 19619347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gain-of-Function Research: Ethical Analysis.
    Selgelid MJ
    Sci Eng Ethics; 2016 Aug; 22(4):923-964. PubMed ID: 27502512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.